Methods: We collected inferior turbinate (IT), UT, and ET from controls, CRSsNP and CRSwNP and nasal polyp tissue (NP). Tissue mRNA expression for type 1 (IFN-γ), 2 (CLC, IL-13) and 3 (IL-17A) inflammatory markers was examined.
Results: Inflammatory signals in ET were stronger than in IT and UT, thus we focused on ET. The pattern of inflammation in CRSsNP ET (n=59) was heterogenous, and there were no significant differences, except in levels of CLC mRNA, compared to controls (n=20) and CRSwNP (n=36). When thresholds using the 90th percentile of expression in controls were defined, 24%, 51% and 22% of CRSsNP ET showed type 1, 2 and 3 inflammation, respectively. In contrast, 81% and 83% of CRSwNP ET and NP had type 2 inflammation. Interestingly, several CRSsNP donors had mixed inflammation, and 10% showed all three types. Among CRSsNP patients, Lund-Mackay scores significantly correlated with type 2, but not type 1 or 3, inflammation.
Conclusions: CRSsNP is a heterogenous disease in the US, and therefore distinct therapeutic strategies may need to be determined based on the type of inflammation.